What is Customer Demographics and Target Market of Haohai Biological Technology Company?

In 2024, this segment was the largest revenue contributor, generating RMB 1.195 billion, a 13.08% increase year-on-year. Hyaluronic acid dermal fillers are a key product, with revenue reaching RMB 0.742 billion in 2024, up 23.23% from the previous year.

The B2C customers in medical aesthetics are primarily middle- and high-income individuals, with a growing younger demographic embracing aesthetic enhancements. This group shows interest in non-invasive procedures and includes a notable male consumer segment prioritizing expert medical advice.

For orthopedic and ophthalmology products, Haohai primarily targets B2B customers like hospitals and clinics. The orthopedic segment generated RMB 0.457 billion in revenue in 2024, experiencing a 4.11% decrease year-on-year, influenced by procurement policies.

The demand in these B2B segments is driven by China's aging population and the increasing prevalence of orthopedic and eye conditions. Hospitals represented a significant portion, accounting for 67.5% of the China orthopedic devices market revenue in 2023.

Haohai Biological Technology's core operations and market leadership are firmly rooted in the People's Republic of China. The company excels in the research, development, manufacturing, and sales of biomedical materials, with a significant concentration of its success in key urban areas known for high consumption of medical aesthetics and advanced healthcare services.

The company demonstrates substantial market leadership across several product categories within China. For instance, it has held the largest market share in orthopedic intra-articular viscoelastic supplements for nine consecutive years, reaching 46.54% as of 2022. In 2021, Haohai secured the leading domestic market share for ophthalmic viscoelastic devices (OVD) at 50.83% for fifteen consecutive years.

In the competitive medical aesthetics sector, Haohai's hyaluronic acid products captured a 6% market share among domestic brands by late 2022. The company also held a combined 28.85% domestic market share for surgical anti-adhesion agents, underscoring its broad impact within specialized medical fields.

Haohai Biological Technology is pursuing strategic international growth, with plans for simultaneous Phase III trials of a topical botulinum toxin product in China and the United States. This indicates a clear intention to enter the North American medical aesthetics market. Additionally, its subsidiary Juva Medical exports radiofrequency (RF) and laser beauty equipment globally, extending the company's geographic reach for specific product lines.

Haohai Biological Technology consistently invests in R&D, with expenses reaching RMB 125.40 million in H1 2024, representing 8.98% of revenue. This fuels the development of new products, such as its fourth-generation hyaluronic acid offerings and the recently approved 'Hai Mei Yue Bai', enhancing functional differentiation and price positioning.

For B2B segments like orthopedics and ophthalmology, the company strengthens its market position through expanded sales channels and outsourced processing services. Adapting to centralized procurement, Haohai aims to maintain market share by ensuring product availability and navigating new pricing structures.

The medical aesthetics segment, showing a 13.08% revenue increase in 2024, suggests effective targeting of middle- and high-income consumers who value quality and safety. The strategy emphasizes product and price diversity in beauty injections to meet evolving consumer demands.

Consistent market leadership in areas like orthopedic intra-articular viscoelastic supplements builds trust and loyalty. The company's overall approach aims to boost customer loyalty and lifetime value through innovative products and a strong market presence across its therapeutic areas.